Healx has commenced its Phase I/II dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310 in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma. 

HLX-4310 is an investigational oral combination of a class I selective HDAC inhibitor and an mTOR inhibitor. 

It represents the first clinical proof point for Healx’s broader rare oncology strategy focused on preventing metastatic recurrence. 

The scientific hypothesis behind the strategy is based on targeting biological programmes that enable micro-metastatic tumours to survive and persist at distant sites and later re-emerge as deadly metastatic disease. 

Osteosarcoma is a rare, aggressive bone cancer that most often affects children, adolescents, and young adults. Patients who develop metastatic disease face particularly poor outcomes, with a five-year survival rate of less than 30%. 

The trial is being advanced in collaboration with the National Pediatric Cancer Foundation’s (NPCF) flagship research program, the Sunshine Project. 

“Metastatic osteosarcoma is so difficult to treat because patients can undergo intensive therapy, reach remission, and still relapse within months or within several years,” said Dr David Warshawsky, Global Head of Metastatic Prevention at Healx. “We believe that HLX-4310 provides a novel and differentiated approach focused on the unique biology hypothesised to drive cancer recurrence, and we are delighted to see it advance into trials.” 

“I’m excited to see this study begin dosing patients and to evaluate a strategy that is explicitly focused on preventing metastatic recurrence,” added Amy Armstrong, Principal Investigator for the Phase I/II HLX-4310 trial. “This trial will evaluate the safety and tolerability of HLX-4310 and assess efficacy, including its potential to reduce cancer recurrence risk.”